HBV core promoter mutations and AKT upregulate S-phase kinase-associated protein 2 to promote postoperative hepatocellular carcinoma progression

Chen, Lubiao; Gu, Lin; Gu, Yurong; Wang, Hongbo; Deng, Meihai; Stamatakis, Zania; Huang, Yuehua; Oo, Ye Htun

DOI: 10.1038/srep35917

License: Creative Commons: Attribution (CC BY)

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (Harvard):
Chen, L, Gu, L, Gu, Y, Wang, H, Deng, M, Stamatakis, Z, Huang, Y & Oo, YH 2016, 'HBV core promoter mutations and AKT upregulate S-phase kinase-associated protein 2 to promote postoperative hepatocellular carcinoma progression', Scientific Reports, vol. 6, 35917. https://doi.org/10.1038/srep35917

Link to publication on Research at Birmingham portal

General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

• Users may freely distribute the URL that is used to identify this publication.
• Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
• Users may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
• Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.
HBV core promoter mutations and AKT upregulate S-phase kinase-associated protein 2 to promote postoperative hepatocellular carcinoma progression

Lubiao Chen1,*, Lin Gu2,*, Yurong Gu1,*, Hongbo Wang2, Meihai Deng3, Zania Stamataki4, Ye Htun Oo4 & Yuehua Huang1,2

Mutations in the hepatitis B virus (HBV) core promoter (CP) have been shown to be associated with hepatocellular carcinoma (HCC). The CP region overlaps HBV X gene, which activates AKT to regulate hepatocyte survival. However, the cooperation between these two cascades in HCC progression remains poorly understood. Here, we assayed virological factors and AKT expression in liver tissues from 56 HCC patients with better prognoses (BHCC, ≥5-year survival) and 58 with poor prognoses (PHCC, <5-year survival) after partial liver resection. Results showed double mutation A1762T/G1764A (TA) combined with other mutation(s) (TACO) in HBV genome and phosphorylated AKT (pAKT) were more common in PHCC than BHCC. TACO and pAKT levels correlated with proliferation and microvascularization but inversely correlated with apoptosis in HCC samples. These were more pronounced when TACO and pAKT co-expressed. Levels of p21 and p27 were decreased in TACO or pAKT overexpressing HCC due to SKP2 upregulation. Levels of E2F1 and both mRNA and protein of SKP2 were increased in TACO expressing HCC. Levels of 4EBP1/2 decreased and SKP2 mRNA level remained constant in pAKT-overexpressing HCC. Therefore, TACO and AKT are two independent predictors of postoperative survival in HCC. Their co-target, SKP2 may be a diagnostic or therapeutic marker.

Hepatocellular carcinoma (HCC) is one of the most common primary malignancies and the third most frequent cause of cancer-related death worldwide1. Risk factors for its development include chronic infection with hepatitis B virus (HBV) or hepatitis C virus, alcohol abuse, aflatoxin exposure and metabolic liver diseases2. Despite a successful vaccination program, HBV is predicted to remain the leading aetiological factor of HCC in patients over 25 years of age in coming decades. Worldwide, more than half of all HCC cases occur in China, where almost 100 million people are seropositive for HBsAg3,4. Among those individuals with chronic HBV infection, several viral factors, including the HBV genotypes C, Aa and F; a high viral load; and viral mutations have been reported to be associated with a high risk of HCC5–7.

The double mutation A1762T/G1764A (TA) in the HBV basal core promoter (CP) region has been widely recognized to be independently associated with HCC5,6,8. In a study of 2762 people with chronic HBV infection who were followed for 13 years, TA was associated with a hazard ratio of 1.73 for HCC development6. In addition to TA, other CP mutations, notably C1653T, T1674C/G, C1766T, T1753V and T1768A, have also been reported to be associated with an increased risk of HCC6–11. Moreover, longitudinal studies have shown that TA is selected earlier, whereas other mutations in the CP region gradually accumulate during HBV-induced...
hepatocarcinogenesis. These other mutations are almost invariably associated with TA, suggesting a key role for TA, but combination with additional mutations in the CP region is necessary for HCC development. Lastly, HBV mutations are not only related to hepatocarcinogenesis but also HCC survival.

Although HCC has been studied for several decades, current treatment for this disease is limited and generally ineffective, and the 5-year survival rate for all disease stages combined is less than 5%. At present, tumour resection or liver transplantation is the only potentially curative surgical treatment. Indeed, survival among patients with HCC is relatively poor, even in patients who undergo surgical resection, and the recurrence rate is high. Nevertheless, a better understanding of the mechanisms of HCC progression may lead to the identification of potential diagnostic markers or therapeutic targets.

AKT is the most frequently activated oncprotein in human cancers, including HCC. Specifically, the hyperactivation of AKT (phosphorylated AKT, pAKT) contributes to carcinogenesis via multiple mechanisms, such as increased cell proliferation, the inhibition of apoptosis, and the abrogation of cell cycle progression checkpoints. Moreover, the overexpression of AKT has been observed in human HCC samples, and AKT may phosphorylate many substrates that are conducive to carcinogenesis and tumour progression. However, the most critical targets for AKT-mediated cell proliferation and oncogenic transformation in HCC have not yet been identified. We previously showed that S-phase kinase-associated protein 2 (SKP2), the most critical downstream effector of AKT, is upregulated by mutations in the HBV CP region, which consequently downregulates p21 to accelerate cell cycle progression, anchorage-independent cell growth, and cellular proliferation. Accordingly, SKP2 plays an important role in HBV CP mutation-induced carcinogenesis.

Despite the importance of AKT and mutations in the HBV CP region in hepatocarcinogenesis, their functional interaction has not yet been linked to prognosis after the surgical removal of cancer. Here, we hypothesized that AKT and HBV CP mutations cooperate to disrupt SKP2, which accelerates tumour proliferation and angiogenesis while inhibiting tumour apoptosis. This mechanism ultimately results in unrestrained HCC growth and consequently shortens survival. In this study, we examined the HBV genome in liver tissue and, based on the expression in the CP region, classified these samples as either wild-type (WT) samples, TA-expressing samples or samples that expressed TA and at least one other mutation (TACO). Specifically, these other mutations were A1768, A/C/G1753, T1766 and T1653. The effect of AKT and HBV CP mutation co-expression on prognosis was evaluated. Finally, our findings imply that concurrent high levels of pAKT and TACO expression may serve as a valuable prognostic marker in patients after surgical resection. Consequently, SKP2 may be a potential therapeutic target in HBV-associated HCC.

Results

Patient characteristics. A total of 139 patients with HBV-related HCC were enrolled after liver resection and followed up for 5 years. Nineteen patients were lost, and another 6 were negative for HBV DNA; the remaining 114 patients were further analysed in the study. All patients were Asian, and almost 85.1% of the cohort was male. Most patients had a background of cirrhosis, and the mean age was 46.1 ± 11.0 years with a mean survival length of 46.6 ± 18 months. The majority (86.0%) of patients had a single tumour, and the mean size of the largest tumour was 7.43 ± 4.50 cm. Notably, the presence of cirrhosis, a larger tumour, multiple lesions, a higher AST, and lower albumin levels were factors that significantly associated with shorter HCC survival. Conversely, age, sex, encapsulation, the TNM classification, the CHILD classification, the AFP level, the ALT level, the bilirubin level, the prothrombin time, the creatinine level, the presence of portal vein thrombosis, and alcohol consumption were not significantly associated with survival (Supplementary Table S1).

Concomitant expression of AKT and HBV CP mutations is associated with HCC prognosis. Of all 114 patients, 56 patients had a better prognosis (BHCC) and 58 patients had a poor (PHCC) prognosis. BHCC and PHCC were defined as survival ≥5 years and survival <5 years, respectively. Moreover, pAKT1 expression was more common in the PHCC population than in the BHCC population (55.2% vs. 32.1%; P = 0.015) (Table 1). Moreover, both immunohistochemistry (IHC) and western blot analyses of HCC specimens indicated that pAKT1 was overexpressed in patients exhibiting shorter survival, although similar levels of total AKT1 were found in both HCC subgroups (Fig. 1).

A virologic analysis of CP mutations from HBV DNA extracted from noncancerous liver tissue showed that patients in the PHCC group developed more mutations than patients in the BHCC group. Furthermore, TACO mutations were more common in the PHCC group than in the BHCC group (72.4% vs. 46.4%; P = 0.007). In contrast, the wild-type CP region was less common among PHCC patients than BHCC patients (10.3% vs. 28.6%; P = 0.018), whereas the TA expression rates (in the absence of other mutations) were similar between the two groups (17.2% vs. 25.0%; P = 0.362) (Table 1).

A Cox regression analysis was used to examine the association between clinicopathological or virologic factors and overall survival after surgical resection in HBV-related HCC. Of all patients included, the cause of death was documented in 19 patients. Liver failure with hepatencephalopathy and subsequent multi-organ failure occurred in 5 patients; progressively enlarged HCC with tumour rupture and shock occurred in 8 patients; lung metastasis and respiratory failure developed in 5 patients; esophageal varices bleeding with hypovolemic shock occurred in 1 patient. According to a univariate analysis, a tumour size >5 cm [hazard ratio [HR] = 3.083, 95% confidence interval [CI] = 1.008–9.434, P = 0.048], HBV DNA > 6.0E+06 copies/ml (HR = 4.283, 95% CI = 1.240–14.796, P = 0.021), TACO mutations (HR = 2.815, 95% CI = 1.010–7.846, P = 0.048), a higher HBsAg titre (HR = 3.987, 95% CI = 1.237–10.712, P = 0.021), and strong pAKT1 expression (HR = 3.096, 95% CI = 1.308–11.605, P = 0.01) were associated with significantly increased mortality due to HCC. After adjusting for other confounding factors, a multivariate analysis showed that HBV DNA > 6.0E+06 copies/ml (HR = 4.496, 95% CI = 1.218–15.116, P = 0.012), TACO mutations expression (HR = 3.007, 95% CI = 1.075–8.745, P = 0.029), and strong pAKT1 expression (HR = 4.022, 95% CI = 1.037–12.942, P = 0.039) were significantly associated with a shorter overall survival (Table 2).
| Variables                      | All patients (n = 114) | BHCC (n = 56) | PHCC (n = 58) | P value |
|-------------------------------|------------------------|---------------|---------------|---------|
| Age (years)                   |                        |               |               |         |
| >50                           | 43 (37.2)              | 19 (33.9)     | 24 (41.4)     | 0.445   |
| ≤50                           | 71 (62.3)              | 37 (66.1)     | 34 (58.6)     |         |
| Male, n (%)                   | 97 (85.1)              | 46 (82.1)     | 51 (87.9)     | 0.380   |
| Cirrhosis, n (%)              |                        |               |               |         |
| Yes                           | 83 (72.8)              | 35 (62.5)     | 48 (82.8)     | 0.020   |
| No                            | 31 (27.2)              | 21 (37.5)     | 10 (17.2)     |         |
| Tumor size                    |                        |               |               |         |
| >5 cm, n (%)                  | 73 (64.0)              | 30 (53.6)     | 43 (74.1)     | 0.048   |
| ≤5 cm, n (%)                  | 41 (36.0)              | 26 (46.4)     | 15 (25.9)     |         |
| Tumor quantity, n (%)         |                        |               |               |         |
| ≥3                            | 11 (9.6)               | 1 (1.8)       | 10 (17.2)     | 0.001   |
| = 2                           | 5 (4.4)                | 3 (5.3)       | 2 (3.5)       | 0.676   |
| = 1                           | 98 (86.0)              | 52 (92.9)     | 46 (79.3)     | 0.057   |
| Encapsulation, n (%)          |                        |               |               |         |
| No                            | 40 (35.1)              | 17 (30.4)     | 23 (39.7)     | 0.331   |
| Yes                           | 74 (64.9)              | 39 (69.6)     | 35 (60.3)     |         |
| CHILD Classification, n (%)   |                        |               |               |         |
| B                             | 9 (7.9)                | 4 (7.1)       | 5 (8.6)       | 1.000   |
| A                             | 105 (92.1)             | 52 (92.9)     | 53 (91.4)     |         |
| TNM classification, n (%)     |                        |               |               |         |
| I                             | 55 (48.2)              | 28 (50.0)     | 27 (46.6)     | 1.000   |
| II+III                        | 59 (51.8)              | 28 (50.0)     | 31 (53.4)     |         |
| AFP (ng/ml), n (%)            |                        |               |               |         |
| >400                          | 47 (41.2)              | 22 (39.3)     | 25 (43.1)     | 0.707   |
| ≤400                          | 67 (58.8)              | 34 (60.7)     | 33 (56.9)     |         |
| Ascites, n (%)                |                        |               |               |         |
| Yes                           | 11 (9.6)               | 5 (8.9)       | 6 (10.3)      | 0.525   |
| No                            | 103 (90.4)             | 51 (91.1)     | 52 (89.7)     |         |
| Portal vein thrombosis, n (%) |                        |               |               |         |
| Positive                      | 5 (4.4)                | 1 (1.8)       | 4 (6.9)       | 0.364   |
| Negative                      | 109 (95.6)             | 55 (98.2)     | 54 (93.1)     |         |
| ALT (U/L), n (%)              |                        |               |               |         |
| >ULN                          | 70 (61.4)              | 34 (60.7)     | 36 (62.1)     | 0.711   |
| ≤ULN                          | 44 (38.6)              | 22 (39.3)     | 22 (37.9)     |         |
| AST (U/L), n (%)              |                        |               |               |         |
| >ULN                          | 41 (36.0)              | 13 (23.2)     | 28 (48.3)     | 0.006   |
| ≤ULN                          | 73 (64.0)              | 43 (76.8)     | 30 (51.7)     |         |
| Albumin (g/L), n (%)          |                        |               |               |         |
| ≥40                           | 80 (70.2)              | 45 (80.4)     | 35 (60.3)     | 0.025   |
| <40                           | 34 (29.8)              | 11 (19.6)     | 23 (39.7)     |         |
| Bilirubin (μmol/L), n (%)     |                        |               |               |         |
| ≥23.9                         | 13 (11.4)              | 6 (10.7)      | 7 (12.1)      | 1.000   |
| <23.9                         | 101 (88.6)             | 50 (89.3)     | 51 (87.9)     |         |
| Prothrombin time (s), n (%)   |                        |               |               |         |
| ≥12                           | 12 (10.5)              | 5 (8.9)       | 7 (12.1)      | 1.000   |
| <12                           | 102 (89.5)             | 51 (91.1)     | 51 (87.9)     |         |
| PLT (10E9/L), n (%)           |                        |               |               |         |
| <170                          | 41 (36.0)              | 20 (35.7)     | 21 (36.2)     | 1.000   |
| ≥170                          | 73 (64.0)              | 36 (64.3)     | 37 (63.8)     |         |
| Alcohol use, n (%)            |                        |               |               |         |
| Yes                           | 41 (36.0)              | 19 (33.9)     | 22 (37.9)     | 0.699   |
| No                            | 73 (60.0)              | 37 (66.1)     | 36 (62.1)     |         |
| HBV DNA (copies/ml), n (%)    |                        |               |               |         |
| >6.0E+06                      | 33 (28.9)              | 10 (19.6)     | 23 (37.9)     | 0.021   |
| ≤6.0E+06                      | 81 (71.1)              | 46 (80.4)     | 35 (62.1)     |         |

Continued
Variables | All patients (n = 114) | BHCC (n = 56) | PHCC (n = 58) | P value
--- | --- | --- | --- | ---
HBsAg (IU/ml), n (%) | | | | |
≤ 500 | 60 (52.6) | 36 (64.3) | 24 (41.4) | 0.025
> 500 | 54 (47.4) | 20 (35.7) | 34 (58.6) | |
HBV genotypes, n (%) | | | | |
B | 66 (57.9) | 32 (57.1) | 34 (58.6) | 1.000
C | 48 (42.1) | 24 (42.9) | 24 (41.4) | |
CP status, n (%) | | | | |
WT | 22 (19.3) | 16 (28.6) | 6 (10.3) | 0.018
TA | 24 (21.1) | 14 (25.0) | 10 (17.2) | 0.362
TACO | 68 (59.6) | 26 (46.4) | 42 (72.4) | 0.007
pAKT1 expression, n (%) | | | | |
High | 50 (43.9) | 18 (32.1) | 32 (55.2) | 0.015
Low | 64 (56.1) | 38 (67.9) | 26 (44.8) | |

Table 1. Both HBV CP mutations and AKT were associated with poor HCC prognosis. Samples in the PHCC group expressed significantly higher levels of pAKT than samples in the BHCC group (55.2% vs. 32.1%; P = 0.015). Moreover, TACO mutations were more common in the PHCC group than in the BHCC group (72.4% vs. 46.4%; P = 0.007). The data were analysed using SPSS, version 15, and the results are expressed as a percentage. Categorical variables were compared with a chi-square test or Fisher’s exact test. P values < 0.05 were considered to indicate significant differences. PHCC, HCC patients with a poor prognosis (less than 5-year survival); BHCC, HCC patients with a better prognosis (more than 5-year survival); ALT, alanine transferase; AST, aspartate transferase; AFP, alpha fetal protein; PLT, platelet; ULN, upper limit of normal; LLN, lower limit of normal.

Figure 1. Expression of pAKT in human HCC. (a) pAKT expression was assessed by immunohistochemistry in liver tissues from patients with a better or poor prognosis. Representative images are shown for three patients in each category (Scale bar, 50 μm). (b) Western blotting confirmed that the protein expression of pAKT corroborated the immunohistochemical analyses of these 6 representative cases. Total AKT (TAKT) and actin levels were used as protein loading controls. (c) Relative protein expressions of pAKT and TAKT quantified by densitometry in livers of 56 BHCC and 58 PHCC, respectively. Bands were relative to protein expression from surrounding non-HCC tissues (C, control, normalized as 1). *P < 0.05 compared with control; **P < 0.05: PHCC vs. BHCC.
Because strong pAKT1 expression and presence of TACO are important independent predictors of survival, a Kaplan-Meier survival analysis was performed to assess the predictive values of high pAKT1 expression, TACO mutations, or the co-expression of both these factors. As expected, the cumulative survival rate calculated based on TACO expression suggested that CP mutations were predictive of overall survival in patients with HBV-related HCC ($P = 0.003$) (Fig. 2a). Likewise, the pAKT1 levels also significantly predicted survival among patients with HBV-related HCC ($P = 0.014$) (Fig. 2b). When these 2 factors were combined, 23 (20.2%) patients expressed low levels of pAKT1 without a TACO mutation, 41 (36.0%) patients expressed low pAKT1 levels with a TACO mutation, 23 (20.2%) patients expressed high pAKT1 levels without a TACO mutation, and 27 (23.6%) patients expressed high pAKT1 levels with a TACO mutation. A Cox regression analysis was used to identify factors associated with HCC prognosis, and the above factors were included in the analysis. Variables with $P < 0.1$ in a univariate analysis were further analysed using a multivariate Cox regression to identify the independent factors associated with poor prognosis. The data showed that a high level of pAKT ($P = 0.039$) and TACO expression ($P = 0.029$) were significantly associated with shorter overall survival in human HBV-related HCC.

| Factors                                      | Multivariate analyses | $P$ value |
|----------------------------------------------|-----------------------|-----------|
| Age > 50 years                               | 1.031 (0.987–1.040)   | 0.336     |
| Male                                         | 1.015 (0.421–2.900)   | 0.839     |
| Cirrhosis                                    | 1.554 (0.652–3.707)   | 0.320     |
| Tumor size > 5 cm                            | 1.602 (0.999–2.215)   | 0.050     |
| Encapsulation                                | 1.634 (0.731–2.201)   | 0.312     |
| Multiple Tumor                               | 0.523 (0.218–2.314)   | 0.287     |
| CHILD Classification: B                      | 0.616 (0.181–2.098)   | 0.439     |
| TNM classification: II + III                 | 1.342 (0.631–3.014)   | 0.330     |
| AFP (ng/mL) > 400                           | 1.000 (1.000–2.030)   | 0.479     |
| Portal vein thrombosis (+)                   | 0.456 (0.104–2.002)   | 0.298     |
| ALT > ULN                                    | 0.990 (0.976–1.003)   | 0.143     |
| AST > ULN                                    | 1.015 (0.995–1.035)   | 0.145     |
| Albumin < LLN                                | 1.003 (0.954–1.054)   | 0.917     |
| Bilirubin > ULN                              | 0.983 (0.939–1.030)   | 0.478     |
| Prothrombin time > ULN                       | 1.022 (0.892–1.043)   | 0.093     |
| PLT < 170                                    | 1.000 (0.995–1.004)   | 0.878     |
| Alcohol use                                  | 0.809 (0.435–1.503)   | 0.502     |
| HBV DNA > 6.0E+06 copies/ml                  | 4.496 (1.218–15.116)  | 0.012     |
| HBsAg > 500 IU/ml                            | 1.887 (1.008–2.976)   | 0.057     |
| HBV genotype C                               | 1.268 (0.724–2.219)   | 0.406     |
| TACO                                         | 3.007 (1.075–8.745)   | 0.029     |
| High pAKT1 expression                        | 4.022 (1.037–12.942)  | 0.039     |

Table 2. Multivariate analyses of clinical, pathological and virologic factors associated with poor prognosis in HCC patients. Strong pAKT expression and TACO expression independently predict postoperative survival among HCC patients. A Cox regression analysis was used to identify factors associated with HCC prognosis, and the above factors were included in the analysis. Variables with $P < 0.1$ in a univariate analysis were further analysed using a multivariate Cox regression to identify the independent factors associated with poor prognosis. The data showed that a high level of pAKT ($P = 0.039$) and TACO expression ($P = 0.029$) were significantly associated with shorter overall survival in human HBV-related HCC.

Figure 2. Association between postoperative survival, intrahepatic HBV CP mutations and pAKT levels. (a) Comparison of survival between patients with and without TACO mutations. (b) Comparison of survival between patients with different levels of pAKT. (c) Combination of intrahepatic TACO mutations and pAKT as a predictor for overall survival. TACO−: Negative for TACO; TACO+: Positive for TACO; AKTlow and AKThigh: low or high levels of pAKT.

Because strong pAKT1 expression and presence of TACO are important independent predictors of survival, a Kaplan-Meier survival analysis was performed to assess the predictive values of high pAKT1 expression, TACO mutations, or the co-expression of both these factors. As expected, the cumulative survival rate calculated based on TACO expression suggested that CP mutations were predictive of overall survival in patients with HBV-related HCC ($P = 0.003$) (Fig. 2a). Likewise, the pAKT1 levels also significantly predicted survival among patients with HBV-related HCC ($P = 0.014$) (Fig. 2b). When these 2 factors were combined, 23 (20.2%) patients expressed low levels of pAKT1 without a TACO mutation, 41 (36.0%) patients expressed low pAKT1 levels with a TACO mutation, 23 (20.2%) patients expressed high pAKT1 levels without a TACO mutation, and 27 (23.6%) patients expressed high pAKT1 levels with a TACO mutation.
expressed high pAKT levels and a TACO mutation. Importantly, postoperative survival was shortest among patients expressing high levels of pAKT and a TACO HBV mutation (Fig. 2c).

Similarly, the Cox proportional hazard model was used to examine the association between clinicopathological and virological factors and disease-free survival after surgical resection of HBV-related HCC. Of the 114 HCC patients, 34 did not have positive results while 80 experienced tumor recurrence or metastasis during the follow-up period. Multivariate analysis of factors associated with tumor progression indicated that ascites, prothrombin time >12 seconds, AST > ULN, portal vein thrombosis, AFP > 400 ng/ml, and positive TACO were associated with a shorter disease-free survival (DFS) (Supplementary Table S2). Higher proportion of patients without TACO had better DFS than patients with TACO infection (19.1% vs. 45.7%, \( P = 0.003 \)). When we stratified patients in subgroups of either presence or absence of TACO mutations, higher proportion of patients with high AKT level than those with low AKT level were found to have shorter DFS (28% vs. 61%, \( P = 0.037 \)) in TACO negative group. However, comparable results of DFS were observed among patients in TACO positive group regardless AKT level (19.5% vs. 22.7% for patients with low or high AKT level, respectively, \( P = 0.589 \)). Kaplan-Meier survival analysis also showed different prediction power of TACO and AKT regarding to tumor free survival in current HBV-related HCC cohort (Supplementary Figure S1a–c).

Overall, these data indicate that the combination of AKT expression and TACO mutations is associated with accelerated tumour progression in HBV-related HCC.

Additive effects of AKT1 and TACO mutations on cell proliferation and sustained human HCC growth. To explore the cellular mechanisms responsible for accelerated HBV-related HCC progression, we evaluated the proliferation, apoptosis, and angiogenesis indices in this HCC cohort (All controls were normalized as 1). Compared with tissues from BHCC patients, tissues from patients with PHCC displayed higher indices of proliferation (5.6 vs. 3.1, \( P = 0.043 \)) and angiogenesis (4.6 vs. 3.1, \( P = 0.031 \)) and a lower index of apoptosis (2.7 vs. 3.5, \( P = 0.046 \)) (Fig. 3a). Similarly, HCC samples expressing high levels of pAKT contained more Ki67-positive cells than samples expressing low levels of pAKT (5.2 vs. 3.1, \( P = 0.014 \)). The proliferation index was also significantly higher in TACO positive tumours than in tumours not infected with a TACO mutant HBV (5.7 vs. 2.9, \( P = 0.034 \)) (Fig. 3b). Patients with high pAKT expression or infection with TACO mutant HBV exhibited 1.6- (\( P = 0.002 \)) and 1.9-fold higher (\( P = 0.001 \)) microvessel density (MVD) than patients with low pAKT levels or patients who did not harbour a TACO mutant HBV infection, respectively (Fig. 3c). However, the apoptotic index inversely correlated with the levels of pAKT and TACO mutations in human HCC (3.0 vs. 3.8 for high pAKT and low PAKT tumours, respectively, \( P = 0.046 \); and 4.0 vs. 5.3 for TACO positive and TACO negative tumours, respectively, \( P = 0.041 \)) (Fig. 3d). Notably, the index of cell proliferation was maximized when high levels of pAKT and a TACO mutation were co-expressed (6.8 vs. 3.2 (\( P = 0.028 \)) or 2.9 (\( P = 0.006 \)) for combined high pAKT and TACO vs. TACO or high pAKT alone, respectively). Furthermore, the microvessel density was maximized (6.3 vs. 3.8 (\( P = 0.013 \)) or 2.9 (\( P = 0.041 \)) for combined high pAKT and TACO vs. TACO or high pAKT alone, respectively) and apoptosis was minimized (2.3 vs. 4.0 (\( P = 0.013 \)) or 4.1 (\( P = 0.041 \)) for TACO or high pAKT alone, respectively) in these samples (Fig. 3e). Taken together, these results suggest that the pAKT levels and TACO mutation status correlate with increased proliferation, angiogenesis index and apoptosis in HCC.

Co-expression of AKT and TACO correlates with the levels of the cell cycle oncosuppressors p21 and p27. We and others showed that cell cycle regulators affect hepatocarcinogenesis and tumour progression by modulating cellular growth and apoptosis1,2,3. Consequently, we measured the expression of cell cycle inhibitors and stimulators in our HCC cohort to further substantiate the probable mechanisms by which AKT1 or TACO mutations affect cell growth. Specifically, p21 and p27 have been identified as important checkpoint regulators for the G1-S and G2 transitions and the progression of the cell cycle, and they are oncosuppressors. Moreover, p21 and p27 inhibition favours the uncontrolled progression of injured or even tumour cells4,5. Therefore, we first compared the levels of p21 and p27 in different HCC subgroups and found that the levels of p21 and p27 were decreased, whereas those of cyclin D1 and cyclin E were increased in the PHCC cohort (Fig. 4a). We then assessed the role of AKT, TACO mutations or the combination of these two factors on cell cycle inhibitors. As expected, the p21 and p27 levels were reduced in HCC samples expressing high levels of pAKT or a TACO mutation compared with samples in which AKT expression was low and samples harbouring wild-type HBV infections. Moreover, these cell cycle regulators were significantly downregulated in tissues simultaneously expressing high levels of pAKT and TACO mutation (Fig. 4b). These data indicate that the p21 and p27 expression levels correlate with the pAKT level or TACO mutation status and corroborate the differences observed between the BHCC and PHCC subgroups. Moreover, the levels of p21 and p27 trended inversely with proliferation (Fig. 4c) and directly correlated with apoptosis (Fig. 4d). Overall, our results show that the pAKT levels and TACO expression predicted a poor HCC prognosis, and reduced expression levels of cell cycle regulators are linked to proliferation and apoptosis.

SKP2 levels correlate with poor prognosis in HBV-related HCC. SKP2 has been identified as a molecule downstream of AKT26 and can target p21 and p27 for proteosomal degradation27. We previously showed that HBV CP mutations increase SKP2 expression and are thus involved in hepatocarcinogenesis28. Here, progressive increases in both the mRNA and protein levels of SKP2 were found from BHCC to PHCC (Fig. 5a) and from HCC with lower levels of pAKT and negative TACO to combined strong pAKT and positive TACO (Fig. 5b). Moreover, the SKP2 level directly correlated with the proliferation index (\( R^2 = 0.5099, P < 0.0001 \)) and MVD (\( R^2 = 0.4213, P < 0.0001 \)) and inversely correlated with apoptosis (\( R^2 = 0.5480, P < 0.0001 \)) (Fig. 5c). As expected, SKP2 protein expression was higher in HCC samples that overexpressed AKT and TACO compared with samples that expressed low levels of AKT and samples harbouring a wild-type CP HBV infection, respectively. Accordingly, SKP2 expression was maximized in HCC samples co-expressing AKT and a TACO mutation.
These results suggested that SKP2 is likely a key factor in the mechanism that leads to pAKT upregulation in HCC, particularly in TACO HBV-associated HCC progression. Surprisingly, the increased level of SKP2 mRNA is likely related only to TACO expression and does not depend on the level of pAKT (Fig. 5b). Indeed, SKP2 mRNA expression was similar in HCC samples expressing low and high levels of pAKT, suggesting that the SKP2 mRNA and protein levels do not correlate and that AKT may mediate SKP2 expression by affecting translation or degradation.

AKT has been shown to modulate mRNA translation primarily via mTORC1, which depends on the downstream effector eIF4E. Specifically, a translation factor named 4E-binding protein (4EBP) binds to eIF4E to impede mRNA translation. As shown in Fig. 5 and Supplementary Figure S2, the levels of 4EBP1 and 4EBP2 were decreased in HCC samples expressing high levels of pAKT and in the PHCC subgroup. This inhibition of 4EBP may lead to eIF4E hyperactivation, which promotes SKP2 translation. Conversely, mutations in the HBV CP region have been found to mediate SKP2 transcription via E2F1. Accordingly, the levels of E2F1 were significantly increased in TACO expressing HCC tissue (Fig. 5b, Supplementary Fig. S2c), suggesting that HBV CP mutations may induce hepatocarcinogenesis and tumour progression via similar mechanisms.

Discussion

Increasing evidence indicates that the aberrant activation of AKT1 is a key oncogenic event in human hepatocarcinogenesis. Specifically, cell- and animal-based experiments show that AKT1 interacts with several HBV proteins to contribute to deterioration in liver disease. Moreover, some studies illustrate that HBV mutations are closely associated with HCC development and tumour progression. Although some growth regulators have been demonstrated to be good prognostic tools in many other common cancers, the connection between HBV CP mutations and AKT1 has not been carefully investigated by examining the prognostic value of HBV-associated HCC. Here, we assessed both virological factors and AKT1 activation in liver tissues obtained from HCC patients.
after tumour resection. Our data demonstrate that the co-expression of activated AKT and TA-combined mutations (TACO) affected postoperative prognosis in human HCC, providing strong genetic evidence that the combination of pAKT and TACO plays a pivotal role in HCC progression.

We found that pAKT levels were higher and TACO mutations were more common in the PHCC subgroup than in the BHCC subgroup, suggesting that the additive effects of pAKT and TACO may play a specific role in the outcome of HBV-associated HCC. Because rapid malignant transformation and tumour progression result in an unfavourable prognosis for patients with cancer, and because pAKT and/or TACO may accelerate HCC tumour cell growth, these molecules may be therapeutic targets. Indeed, our results confirmed that high pAKT levels together with TACO expression resulted in HCC progression by increasing cell proliferation and angiogenesis and conferring anti-apoptotic advantages to the liver lesion. This finding is consistent with the fact that AKT overexpression and TA mutations promote hepatocarcinogenesis and tumour progression in AKT transgenic mice and human HCC samples, respectively.15,17. These observations, together with the observed aberrant Ki67 expression, MVD, and apoptotic indices in PHCC, support the hypothesis that the stabilization of pAKT and the accumulation of mutations in the CP region of the HBV genome have a potential prognostic role in HBV-associated HCC.

Moreover, we found that impairment in cell cycle regulators influenced the overall postoperative survival of our HCC cohort. The decreased levels of cell cycle inhibitors and concurrently higher levels of pAKT and TACO expression in the PHCC subgroup implicate p21 and p27 in the growth and progression of human liver lesions. This behaviour can be attributed to enhanced pro teaseomal degradation because higher SKP2 levels were accompanied by high levels of pAKT and TACO expression in the PHCC subgroup. Other groups and our group observed that SKP2 levels were directly correlated with the proliferation and MVD of HCC and inversely correlated with the apoptosis index and survival. Accordingly, forced SKP2 expression in human HCC SKI cells triggered a strong increase in proliferation and a decline in the expression of cell cycle regulators.23.
The HBV CP region overlaps with the coding sequence for the C-terminus in the HBV X (HBx) gene. The HBx protein is an important oncoprotein in HCC pathogenesis, and mutations in this region may alter its biological functions, thereby increasing its oncogenicity. Moreover, pAKT and TACO may exert synergistic effects instead of additive effects on HCC survival. The concomitant expression of AKT1 and HBV CP mutations corresponding to the CP mutations that are clinically associated with HCC promote tumour progression.

Compared with previous studies that have analysed the impact of HBV on HCC prognosis, our findings are significant for the following reasons. First, previous studies have only analysed virological factors or oncogenes associated with HCC progression, whereas our study showed that the concomitant expression of AKT1 and HBV mutant CPs is associated with HCC progression. Second, many clinical studies have evaluated factors that are related to HCC prognosis based on 3-year survival; however, we demonstrated that both HBV CP mutations and AKT1 expression increased cell proliferation and angiogenesis, likely via their co-target SKP2.

One limitation of this study is the absence of in vitro experiments to corroborate the contribution of pAKT and TACO to HCC progression via the dysregulation of SKP2. However, in vitro and ex vivo studies have demonstrated that abolishing AKT can increase 4EBP1/2 expression to enhance their binding to eIF4E, which...

---

Figure 5. Effect of AKT and TACO on the levels of SKP2 via independent pathways. (a) Representative Western blot analysis of SKP2, transcription factor E2F1 and translation inhibitor 4EBP1/2 (upper), relative protein (middle) and mRNA levels (lower) of SKP2, in the BHCC and PHCC subgroups as well as paracancerous tissues, which served as a control. P < 0.05: compared with control. P < 0.05: BHCC vs. PHCC. (b) Above protein expression by Western blot analysis (upper), relative protein (middle) and mRNA levels (lower) in HCC with different levels of AKT expression and HBV CP status. P < 0.05: compared with control. P < 0.05: HCC with TACO+/AKT+ vs. TACO−/AKT− or TACO−/AKT+ vs. TACO+/AKT− or control. (c) Correlation of SKP2 protein levels with proliferation index, angiogenesis (MVD), and apoptosis index in 114 human HBV-associated HCC cases. Protein expression quantified by densitometry was shown as a relative value compared to the control. All controls were normalized as 1.
Correlation between pAKT and TACO mutations in HCC. The pAKT levels were similar in human HBV-related HCC samples with or without CP mutations in the HBV genome \( (P = 0.186) \). Categorical variables were analysed with a chi-square test. \( P < 0.05 \) was considered to indicate a significant difference.

| HBV CP Status | TACO − | TACO + | \( P \) |
|---------------|--------|--------|-------|
| pAKT expression Low, n(%) | 23 (20.2%) | 41 (36.0%) | 0.186 |
| High, n(%) | 23 (20.2%) | 27 (23.6%) | |

Materials and Methods

Patients and samples. Consecutive HCC patients who underwent total liver tumour resections between January 2004 and March 2007 at the Third Affiliated Hospital of Sun Yat-sen University and who had a history of chronic hepatitis B infection and were currently positive for HBsAg were included. Patients co-infected with human immunodeficiency virus (HIV), hepatitis C virus, or hepatitis D virus were excluded. All patients were followed up until May 2012, and their medical records and clinicopathological data were retrospectively reviewed. Overall survival was defined as the interval between the date of surgery and date of last follow-up or HCC-related death, whichever occurred first. After surgical resection, the matched paired tumour and corresponding surrounding non-tumourous liver tissue samples were immediately frozen at \(-80^\circ\text{C}\), and serum samples were stored at \(-30^\circ\text{C}\) (details are provided in the supplementary materials).

All experimental protocols in this project were approved by the Ethical Committee of the Third Affiliated Hospital of the Sun Yat-sen University (EC-TAH-SYSU [2013]–2–43). The methods were performed in accordance with the approved guidelines. Written informed consent was obtained from all patients in this study.

Virological assay. HBV DNA was extracted from noncancerous liver tissues adjacent to the tumour as previously described\(^9\). The HBV DNA level in the liver tissue was measured using the ABI 7300 TaqMan platform (Life Technologies, Carlsbad, CA). The DNA sequences were aligned using Seqman II and EdiSeq software (DNASTAR Inc., Madison, WI) and compared to consensus sequences of the respective HBV genotype. The mutations TA, A1768, A/C/G1753, T1766, and T1653 in the CP region were verified by direct sequencing.

Proliferation and apoptotic indices. Cell proliferation in tissues was assayed by immunoperoxidase staining with anti-Ki67 antibody. The proliferation index was determined by counting the number of positive cells per high-power field (HPF, 400× magnification) per 3000 hepatocytes. The apoptotic indices were measured by staining figures with the ApoTag peroxidase in situ apoptosis kit (Millipore, Billerica, MA) using 3000 hepatocytes.

Definition of pAKT levels. All specimens stained for pAKT were scored by 2 independent pathologists according to the proportion and intensity of positive cells within 10 microscopic visual field per slide (200-fold magnification)\(^8\). Briefly, a proportion score, which represented the estimated proportion of positively stained tumor cells, was classified: <10% as 0; 10–25% as 1; 26–50% as 2; 51–75% as 3; and >75% as 4. An intensive score, which represented the average intensity of the positive tumor cells, was defined: no staining as 0; weak as 1; moderate as 2; strong as 3. The proportion and intensity scores were then multiplied to obtain a total score, and the cutoff point was used to analyze the pAKT value in specimens. Within range of 0–12, cut point \( \leq 3 \) or \( >3 \) indicate low and high gene expression, respectively.

Antibodies, western blotting and immunohistochemistry. The experimental protocol and additional details are provided in the supplementary materials.

Statistical analysis. Continuous variables are expressed as the mean ± standard deviation. Categorical variables are expressed as numbers and percentages. Continuous variables were compared with a 2-sided Student’s \( t \)-test or a Mann-Whitney \( U \)-test depending on the distribution. Categorical variables were compared with a chi-square test or Fisher’s exact test. A Cox regression analysis was used to identify clinicopathological and virological factors associated with postoperative survival. The Kaplan-Meier method was used to estimate the
cumulative survival probability. The log-rank method was used to compare survival curves between groups. P values less than 0.05 were considered to indicate significant differences, and the data were analysed using SPSS software, version 15 (SPSS Inc. Chicago, IL).

References
1. Forner, A., Llovet, J. M. & Bruix, J. Hepatocellular carcinoma. *Lancet* **379**, 1245–1255 (2012).
2. El-Serag, H. B. & Rudolph, K. L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. *Gastroenterology* **132**, 2557–2576 (2007).
3. Jamal, A. et al. Global cancer statistics. *CA Cancer J Clin* **61**, 69–90 (2011).
4. Yin, J. et al. Distribution and hepatocellular carcinoma-related viral properties of hepatitis B virus genotypes in Mainland China: a community-based study. *Cancer Epidemiol Biomarkers Prev* **19**, 777–786 (2010).
5. Yuen, M. F. et al. Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels. *Gut* **57**, 98–102 (2008).
6. Yang, H. I. et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. *J Natl Cancer Inst* **100**, 1134–1143 (2008).
7. Chen, C. et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. *JAMA* **295**, 65–73 (2006).
8. Liu, S. et al. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. *J Natl Cancer Inst* **101**, 1066–1082 (2009).
9. Guo, X., Jin, Y., Qian, G. & Tu, H. Sequential accumulation of the mutations in core promoter of hepatitis B virus is associated with the development of hepatocellular carcinoma in Qidong, China. *J Hepatol* **49**, 718–725 (2008).
10. Xie, J. et al. Interaction of signal transducer and activator of transcription 3 polymorphisms with hepatitis B virus mutations in hepatocellular carcinoma. *Hepatology* **57**, 2369–2377 (2013).
11. Yin, J. et al. Association between the various mutations in viral core promoter region to different stages of hepatitis B, ranging of asymptomatic carrier state to hepatocellular carcinoma. *Am J Gastroenterol* **106**, 81–92 (2011).
12. Chou, Y. C. et al. Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma. *Gut* **57**, 91–97 (2008).
13. Kuang, S. Y. et al. Specific mutations of hepatitis B virus in plasma predict liver cancer development. *Proc Natl Acad Sci USA* **101**, 3575–3580 (2004).
14. Bai, X. et al. Temporal acquisition of sequential mutations in the enhancer II and basal core promoter of HBV in individuals at high risk for hepatocellular carcinoma. *Carcinogenesis* **32**, 63–68 (2011).
15. Yeh, C. T. et al. Hepatitis B virus-DNA level and basal core promoter A1762T/G1764A mutation in liver tissue independently predict postoperative survival in hepatocellular carcinoma. *Hepatology* **52**, 1922–1933 (2010).
16. Xie, Y. et al. Precore/core region mutations in hepatitis B virus DNA predict postoperative survival in hepatocellular carcinoma. *PLoS One* **10**, e0133593 (2015).
17. Ito, C. et al. AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathways. *Hepatology* **55**, 833–845 (2012).
18. Bosetti, C., Turati, F. & La Vecchia, C. Hepatocellular carcinoma epidemiology. *Best Pract Res Clin Gastroenterol* **28**, 753–770 (2014).
19. Bhashkar, P. T. & Hay, N. The two TORCs and Akt. *Nat Rev Genes Dev* **7**, 229–242 (2006).
20. Robey, R. B. & Hay, N. Is Akt the “Warburg kinase”?-Akt-energy metabolism interactions and oncogenesis. *Semin Cancer Biol* **19**, 25–31 (2009).
21. Lawlor, M. A. & Alessi, D. R. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? *J Cell Sci* **114**, 2903–2910 (2001).
22. Huang, Y., Tong, S., Tai, A. W., Hussain, M. & Lok, A. S. Hepatitis B virus core promoter mutations contribute to hepatocarcinogenesis by deregulating SKP2 and its target, p21. *Gastroenterology* **141**, 1412–1421, 1421 e1–5 (2011).
23. Calvisi, D. F. et al. SKP2 and CKS1 promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis. *Gastroenterology* **137**, 1816–1826, e1–10 (2009).
24. Thorgeirsson, S. S. & Grisham, J. W. Molecular pathogenesis of human hepatocellular carcinoma. *Nat Genet* **31**, 339–346 (2002).
25. Luo, L. et al. Hepatitis B virus X protein expression increases expression of p21 (Cip-1/WAF1/MDA6) and p27 (Kip-1) in primary mouse hepatocytes, leading to reduced cell cycle progression. *Hepatology* **34**, 906–917 (2001).
26. Hay, N. & Sonenberg, N. Upstream and downstream of mTOR. *EMBO J* **28**, 1816–1826 (2009).
27. Frescas, D. & Pagano, M. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. *Nat Rev Cancer* **8**, 438–449 (2008).
28. Nogueira, V. et al. Akt-dependent Skp2 mRNA translation is required for exiting contact inhibition, oncogenesis, and adipogenesis. *EMBO J* **31**, 1134–1146 (2012).
29. Huang, Y., Tai, A. W., Tong, S. & Lok, A. S. HBV core promoter mutations promote cellular proliferation through E2F1-mediated upregulation of S-phase kinase-associated protein 2 transcription. *J Hepatol* **58**, 1068–1073 (2013).
30. Yang, Y. et al. beta-Arrestin1 enhances hepatocellular carcinogenesis through inflammation-mediated Akt signalling. *Nat Commun* **6**, 7369 (2015).
31. Rawat, S. & Bouchard, M. J. The hepatitis B virus (HBV) HBx protein activates AKT to simultaneously regulate HBV replication and hepatocyte survival. *J Viral* **89**, 999–1012 (2015).
32. Kay, A. & Zoulim, F. Hepatitis B virus genetic variability and evolution. *Virus Res* **127**, 164–176 (2007).
33. Pang, R. et al. P11 interacts with a specific serine-proline motif of hepatitis B virus X-protein to enhance hepatocarcinogenesis. *Gastroenterology* **132**, 1088–1103 (2007).
34. Zhang Y. et al. MiR-20a induces cell radio resistance by activating the PTEN/PJ3K/Akt signaling pathway in hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys* **92**, 1132–1140 (2015).

Acknowledgements
We thank Professor Anna Lok (University of Michigan) for supervising the preliminary stage of the work and providing valuable comments on this manuscript. This study was supported in part by grants from the National Natural Science Foundation of China (81371866), the International Cooperation Project of Guangzhou Science and Technology Program (2016201604030021), and the National Grant Program on Key Infectious Diseases (2014ZX10002002-002, 2014ZX10002002-001, 2014ZX10002002-002-002, and 2014ZX10002002-002-003).
Author Contributions
L.C., L.G. and Y.G. contributed equally to this work. L.C. designed and performed the experiments and generated figures. L.G. designed and performed the experiments and analysed the data. Y.G. designed and performed experiments and drafted the manuscript. H.W. performed experiments. M.D. collected samples and patient information and prepared the ethics approval. Z.S., Y.O. and Y.H. reviewed the manuscript. Y.H. also provided advice on study design, supervised experiments, assisted in data analysis, and provided funding.

Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep
Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Chen, L. et al. HBV core promoter mutations and AKT upregulate S-phase kinase-associated protein 2 to promote postoperative hepatocellular carcinoma progression. Sci. Rep. 6, 35917; doi: 10.1038/srep35917 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2016